The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs
Open accessAbstract
DNA topoisomerases are the targets of important anticancer and antibacterial drugs. Camptothecins and novel noncamptothecins in clinical development (indenoisoquinolines and ARC-111) target eukaryotic type IB topoisomerases (Top1), whereas human type IIA topoisomerases (Top2alpha and Top2beta) are the targets of the widely used anticancer agents etoposide, anthracyclines (doxorubicin, daunorubicin), and mitoxantrone. Bacterial type II topoisomerases (gyrase and Topo IV) are the targets of quinolones and aminocoumarin antibiotics. This review focuses on the molecular and biochemical characteristics of topoisomerases and their inhibitors. We also discuss the common mechanism of action of topoisomerase poisons by interfacial inhibition and trapping of topoisomerase cleavage complexes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.
Hsiang, Y. H., Hertzberg, R., Hecht, S., & Liu, L. F. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38654-4 · Cited by 2,362
Cellular roles of DNA topoisomerases: a molecular perspective
Wang, J. C. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm831 · Cited by 2,353
Topoisomerase I inhibitors: camptothecins and beyond
Pommier, Y. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1977 · Cited by 2,277
Self-citationWall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. T., & Sim, G. A. (1966) · Journal of the American Chemical Society · doi:10.1021/ja00968a057 · Cited by 2,258
Supercoiling of the DNA template during transcription.
Liu, L. F., & Wang, J. C. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.20.7024 · Cited by 1,962
Targeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2607 · Cited by 1,791
DNA gyrase: an enzyme that introduces superhelical turns into DNA.
Gellert, M., Mizuuchi, K., O'Dea, M. H., & Nash, H. A. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.11.3872 · Cited by 1,204
Cell cycle kinases as therapeutic targets for cancer
Lapenna, S., & Giordano, A. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2907 · Cited by 905
Tewey, K. M., Chen, G. L., Nelson, E. M., & Liu, L. F. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)47282-6 · Cited by 887 · cited 1×
“Inhibition of Top2 catalytic activity without trapping cleavage complexes is also observed for DNA intercalators at drug concentrations that alter DNA structure, thereby preventing Top2 from binding DNA (step 1 in Figure 5A) or from forming Top2cc (step 3) (Pommier et al., 1984; Tewey et al., 1984).”
DNA topoisomerase II and its growing repertoire of biological functions
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2608 · Cited by 885
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,649
Targeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,518
Cellular senescence promotes adverse effects of chemotherapy and cancer relapse
Demaria, M., O'Leary, M. N., Chang, J., Shao, L., Liu, S., Alimirah, F., Koenig, K., Le, C., Mitin, N., Deal, A. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0241 · Cited by 1,338
“Doxo intercalates into DNA and prevents topoisomerase II from resealing the DNA double strand break, which the enzyme creates to relieve torsional stress (16).”
BackgroundMechanism of Quinolone Action and Resistance
Aldred, K. J., Kerns, R. J., & Osheroff, N. (2014) · Biochemistry · doi:10.1021/bi5000564 · Cited by 1,282
cGAS is essential for cellular senescence
Yang, H., Wang, H., Ren, J., Chen, Q., & Chen, Z. J. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705499114 · Cited by 1,009
Roles of eukaryotic topoisomerases in transcription, replication and genomic stability
Pommier, Y., Sun, Y., Huang, S.-Y. N., & Nitiss, J. L. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.111 · Cited by 950
Self-citationDrugging Topoisomerases: Lessons and Challenges
Pommier, Y. (2013) · ACS Chemical Biology · doi:10.1021/cb300648v · Cited by 839
Self-citationKadoch, C., & Crabtree, G. R. (2015) · Science Advances · doi:10.1126/sciadv.1500447 · Cited by 828
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Pommier, Y., O’Connor, M. J., & de Bono, J. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9246 · Cited by 739
Self-citationDoxorubicin, DNA torsion, and chromatin dynamics
Yang, F., Teves, S. S., Kemp, C. J., & Henikoff, S. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.12.002 · Cited by 695
Exploiting bacterial DNA gyrase as a drug target: current state and perspectives
Collin, F., Karkare, S., & Maxwell, A. (2011) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3557-z · Cited by 606
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
Wu, C.-C., Li, T.-K., Farh, L., Lin, L.-Y., Lin, T.-S., Yu, Y.-J., Yen, T.-J., Chiang, C.-W., & Chan, N.-L. (2011) · Science · doi:10.1126/science.1204117 · Cited by 523
Antimicrobial resistance, mechanisms and its clinical significance
Abushaheen, M. A., Muzaheed, Fatani, A. J., Alosaimi, M., Mansy, W., George, M., Acharya, S., Rathod, S., Divakar, D. D., Jhugroo, C., et al. (2020) · Disease-a-Month · doi:10.1016/j.disamonth.2020.100971 · Cited by 511
Recent applications of multicomponent reactions in medicinal chemistry
Slobbe, P., Ruijter, E., & Orru, R. V. A. (2012) · MedChemComm · doi:10.1039/c2md20089a · Cited by 484
Human topoisomerases and their roles in genome stability and organization
Pommier, Y., Nussenzweig, A., Takeda, S., & Austin, C. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00452-3 · Cited by 464
Self-citationHuman RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition
Berti, M., Ray Chaudhuri, A., Thangavel, S., Gomathinayagam, S., Kenig, S., Vujanovic, M., Odreman, F., Glatter, T., Graziano, S., Mendoza-Maldonado, R., et al. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2501 · Cited by 452
Anthraquinones As Pharmacological Tools and Drugs
Malik, E. M., & Müller, C. E. (2016) · Medicinal Research Reviews · doi:10.1002/med.21391 · Cited by 448
Nakada, T., Sugihara, K., Jikoh, T., Abe, Y., & Agatsuma, T. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00744 · Cited by 442
Adsorption of ciprofloxacin from water: A comprehensive review
Igwegbe, C. A., Oba, S. N., Aniagor, C. O., Adeniyi, A. G., & Ighalo, J. O. (2021) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2020.09.023 · Cited by 441
Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages
Covarrubias, A. J., Kale, A., Perrone, R., Lopez-Dominguez, J. A., Pisco, A. O., Kasler, H. G., Schmidt, M. S., Heckenbach, I., Kwok, R., Wiley, C. D., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-00305-3 · Cited by 420
New Mechanistic and Functional Insights into DNA Topoisomerases
Chen, S. H., Chan, N.-L., & Hsieh, T.-S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-061809-100002 · Cited by 369
Indole in the target-based design of anticancer agents: A versatile scaffold with diverse mechanisms
Dadashpour, S., & Emami, S. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.02.065 · Cited by 343
Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2)
Pommier, Y., Huang, S.-Y. N., Gao, R., Das, B. B., Murai, J., & Marchand, C. (2014) · DNA Repair · doi:10.1016/j.dnarep.2014.03.020 · Cited by 336
Self-citationKaragöz, G. E., Acosta-Alvear, D., & Walter, P. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033886 · Cited by 310
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
Mutagenic Processing of Ribonucleotides in DNA by Yeast Topoisomerase I
Kim, N., Huang, S.-Y. N., Williams, J. S., Li, Y. C., Clark, A. B., Cho, J.-E., Kunkel, T. A., Pommier, Y., & Jinks-Robertson, S. (2011) · Science · doi:10.1126/science.1205016 · Cited by 291
Self-citationCellular functions of the protein kinase ATM and their relevance to human disease
Lee, J.-H., & Paull, T. T. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00394-2 · Cited by 289
Contemporary Challenges in the Design of Topoisomerase II Inhibitors for Cancer Chemotherapy
Bailly, C. (2012) · Chemical Reviews · doi:10.1021/cr200325f · Cited by 288
Interfacial inhibitors: targeting macromolecular complexes
Pommier, Y., & Marchand, C. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3404 · Cited by 259
Self-citationPayload diversification: a key step in the development of antibody–drug conjugates
Conilh, L., Sadilkova, L., Viricel, W., & Dumontet, C. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01397-y · Cited by 257
Trapping Poly(ADP-Ribose) Polymerase
Shen, Y., Aoyagi-Scharber, M., & Wang, B. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222448 · Cited by 230
Cancer Targeting and Drug Delivery Using Carbon-Based Quantum Dots and Nanotubes
Pardo, J., Peng, Z., & Leblanc, R. (2018) · Molecules · doi:10.3390/molecules23020378 · Cited by 226
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183
“The main mechanisms of actions of anthracyclines, including doxorubicin, are inhibition of DNA and RNA synthesis by intercalation between base pairs of the DNA/RNA strands, and interference with the topoisomerase II enzyme, leading to double-strand breaks.(26) This results in a DNA damage response, including activatio…”
BackgroundMurai, J., Thomas, A., Miettinen, M., & Pommier, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.05.009 · Cited by 172
Self-citationCanon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0710 · Cited by 152
Identification of the MMS22L-TONSL Complex that Promotes Homologous Recombination
Duro, E., Lundin, C., Ask, K., Sanchez-Pulido, L., MacArtney, T. J., Toth, R., Ponting, C. P., Groth, A., Helleday, T., & Rouse, J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.10.023 · Cited by 125
Crippa, V., D’Agostino, V. G., Cristofani, R., Rusmini, P., Cicardi, M. E., Messi, E., Loffredo, R., Pancher, M., Piccolella, M., Galbiati, M., et al. (2016) · Scientific Reports · doi:10.1038/srep22827 · Cited by 101
Bossaert, M., Pipier, A., Riou, J.-F., Noirot, C., Nguyên, L.-T., Serre, R.-F., Bouchez, O., Defrancq, E., Calsou, P., Britton, S., et al. (2021) · eLife · doi:10.7554/elife.65184 · Cited by 97
Tang, S.-W., Thomas, A., Murai, J., Trepel, J. B., Bates, S. E., Rajapakse, V. N., & Pommier, Y. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0443 · Cited by 94
Self-citationFransson, Å., Glaessgen, D., Alfredsson, J., Wiman, K. G., Bajalica-Lagercrantz, S., & Mohell, N. (2016) · Journal of Ovarian Research · doi:10.1186/s13048-016-0239-6 · Cited by 65
“The main mechanisms of action of doxorubicin are inhibition of DNA and RNA synthesis by intercalation between base pairs of the DNA/RNA strands, and interference with the topoisomerase II enzyme, leading to double-strand breaks [35].”
BackgroundShaojun, C., Li, H., Haixin, H., & Guisheng, L. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1414754 · Cited by 54
p53-mediated heterochromatin reorganization regulates its cell fate decisions.
Mungamuri, S. K., Benson, E. K., Wang, S., Gu, W., Lee, S. W., & Aaronson, S. A. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2271 · Cited by 53
Jing, P., Cao, S., Xiao, S., Zhang, X., Ke, S., Ke, F., Yu, X., Wang, L., Wang, S., Luo, Y., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.10.003 · Cited by 37
Iron Chelators with Topoisomerase-Inhibitory Activity and Their Anticancer Applications
Rao, V. A. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4877 · Cited by 37
Adeno-associated virus inverted terminal repeats stimulate gene editing
Hirsch, M. L. (2015) · Gene Therapy · doi:10.1038/gt.2014.109 · Cited by 32
Drug repurposing: An emerging strategy in alleviating skin cancer
Kumbhar, P., Kole, K., Yadav, T., Bhavar, A., Waghmare, P., Bhokare, R., Manjappa, A., Jha, N. K., Chellappan, D. K., Shinde, S., et al. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175031 · Cited by 28
Nogalski, M. T., & Shenk, T. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2017734117 · Cited by 25
“UV-C causes helix-distorting lesions in DNA, such as pyrimidine(6-4)pyrimidone photoproducts and cyclobutane pyrimidine dimers (52), that can subsequently be converted into DSBs during DNA replication; whereas zeocin (88), etoposide (89), and HCMV infection (90) directly induce DSBs.”
BackgroundCai, T.-Y., Liu, X.-W., Zhu, H., Cao, J., Zhang, J., Ding, L., Lou, J.-S., He, Q.-J., & Yang, B. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0490 · Cited by 19
“Camptothecin (CPT), a natural product isolated from Camptotheca acuminata Decne, was originally discovered because of its antitumor activity, and the mechanism of action was later demonstrated to be the accumulation of Topoisomerase I–DNA adducts, observed both in vitro and in vivo (14-17).”
BackgroundMishra, N., Tiwari, V. K., & Schmidt, R. R. (2020) · Carbohydrates in Drug Discovery and Development · doi:10.1016/b978-0-12-816675-8.00001-4 · Cited by 17
(2019) · doi:10.1101/609438 · Cited by 15
Hu, X., Wu, X., Liu, H., Cheng, Z., Zhao, Z., Xiang, C., Feng, X., Takeda, S., & Qing, Y. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.27082 · Cited by 9
Jeon, K.-H., Park, S., Shin, J.-H., Jung, A.-R., Hwang, S.-Y., Seo, S. H., Jo, H., Na, Y., & Kwon, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114999 · Cited by 9
Osterman, A., & Mondragón, A. (2022) · eLife · doi:10.7554/elife.72702 · Cited by 9
Rebolledo, L. P., Anil Kumar Jeeja, P., Danai, L., Binte Huq, T., Afonin, K. A., & Vivero-Escoto, J. L. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c15253 · Cited by 4
Metadata
- Authors
- Pommier, Y., Leo, E., Zhang, H., & Marchand, C.
- Venue
- Chemistry & Biology
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 17
- Issue
- 5
- Pages
- 421-433
- ISSN
- 1074-5521 (ISSN-L)
- OpenAlex
- W2068577449
- Cited by
- 1,829
- References
- 103
- FWCI
- 29.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.